register

News & Trends - Biotechnology

Ex-AusBiotech CEO to spearhead manufacturing technology peak body

Health Industry Hub | April 16, 2024 |

The former CEO of AusBiotech is set to lead the peak body advocating for manufacturing technology suppliers and users in the precision engineering and advanced manufacturing domain.

On May 1st, Lorraine Maxwell (Chiroiu) assumes leadership at AMTIL (Australian Manufacturing Technology Institute Limited), succeeding outgoing CEO Shane Infanti, who held the position for 25 years.

Lorraine spearheaded AusBiotech’s efforts to grow and showcase Australia’s prowess in biotechnology, shaping policy shifts with both state and Federal governments, fostering and expanding its extensive membership base of 3000, and achieving milestones through strategic alliances and collaborations.

Her pivotal contributions extend to the development and advocacy of manufacturing policies. Presently, she chairs CSIRO’s Manufacturing Business Unit Advisory Group and holds a Ministerial appointment to the Trade 2040 Taskforce, underscoring her influential role in shaping the trajectory of manufacturing and trade in Australia.

AMTIL President, Brigitte Stavar, said “We are so delighted to have secured Lorraine in this role. Her skill set is exactly what we were looking for and we are sure she will be able to take AMTIL on their next phase of evolution. This next phase includes a stronger level of advocacy and a voice for our local manufacturers. Lorraine’s expertise in this area is definitely a key reason why she was successful through the application process.”

Shane indicated he had mixed feelings about leaving AMTIL after such a long tenure. “When I was employed as CEO in 1999, I couldn’t have imagined the journey it would take me on, the friendships I would make and the impact our small organisation would have on the manufacturing sector in Australia.

“I am genuinely excited about handing over to Lorraine. Her fresh set of eyes, strategic mindset and renewed enthusiasm will take us a long way into the future.”

Lorraine congratulated Shane on his significant legacy and contribution to AMTIL, saying “It is a great privilege to join an organisation that is successful, solid and has a view to the future. I look forward to leading AMTIL with the Board to further build Australian manufacturing.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


Medical

NSW Health to settle class action

NSW Health to settle ‘largest’ class action

Health Industry Hub | April 29, 2024 |

A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]

More


News & Trends - Pharmaceuticals

Lilly's first-in-class therapy PBS listed for early breast cancer after 15-year gap

Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap

Health Industry Hub | April 29, 2024 |

Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]

More


News & Trends - Pharmaceuticals

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

Health Industry Hub | April 29, 2024 |

Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]

More


News & Trends - Pharmaceuticals

PBAC recommendation to reshape prescribing in heart failure

PBAC recommendation to reshape prescribing in heart failure

Health Industry Hub | April 29, 2024 |

Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]

More


This content is copyright protected. Please subscribe to gain access.